FHL2 Silencing Reduces Wnt Signaling and Osteosarcoma Tumorigenesis In Vitro and In Vivo

• Julia Brun,

  Affiliations INSERM UMR 606, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

  ⨯
• François-Xavier Dieudonné,

  Affiliations INSERM UMR 606, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

  ⨯
• Caroline Marty,

  Affiliations INSERM UMR 606, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

  ⨯
• Judith Müller,

  Affiliation Urologische Klink/Frauenklinik, Klinikum der Universität Freiburg and BIOSS Centre for Biological Signalling Studies, Freiburg, Germany

  ⨯
• Roland Schüle,

  Affiliation Urologische Klink/Frauenklinik, Klinikum der Universität Freiburg and BIOSS Centre for Biological Signalling Studies, Freiburg, Germany

  ⨯
• Ana Patiño-García,

  Affiliation Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain

  ⨯
• Fernando Lecanda,

  Affiliation Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain

  ⨯
• Olivia Fromigué,

  Affiliations INSERM UMR 606, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

  ⨯
• Pierre J. Marie

  * E-mail: pierre.marie@inserm.fr

  Affiliations INSERM UMR 606, Paris, France, Université Paris Diderot, Sorbonne Paris Cité, Paris, France

  ⨯